Abstract A184: Activity of plinabulin in tumor models with Kras mutations

G. Kenneth Lloyd(Culham Centre for Fusion Energy), Lan Huang(University of California, Irvine), Jessica Dalsing-Hernandez(Translational Genomics Research Institute), Kari Kotlarczyk(Translational Genomics Research Institute), Steffan T. Nawrocki(University of Arizona), Paul Gonzales(Translational Genomics Research Institute), Gloria Lee(Florida State University), Lihua Du(University of Arkansas for Medical Sciences), Jennifer S. Carew(University of Arizona)
Molecular Cancer Therapeutics
December 1, 2015
10.1158/1535-7163.targ-15-a184
Cited by 0

Related Papers

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells
|Cancer Research|2005|324
Targeting HSP90 for cancer therapy
|British Journal of Cancer|2009|320